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AbstrAct
The aim of this article is to review the role of Health 
Technology Assessment (HTA) organisations in 
appraising and recommending innovative cardiovascular 
technologies. We consider how bias impairs the quality 
of evidence from clinical trials involving cardiovascular 
healthcare technologies. Finally, we provide 
recommendations to HTA organisations to take account of 
bias when making guideline recommendations.
Clinical research studies of medical devices, diagnostics 
and interventions in cardiovascular healthcare are 
susceptible to impairment through bias. While HTA 
organisations, such as the National Institute of Health 
and Care Excellence, may require reviewers to take 
account of bias, there are uncertainties as to how this is 
achieved, especially in cardiovascular technology trials. 
This becomes more relevant given that large trials are 
few in number; therefore, the quality of evidence from 
an individual trial may have a large bearing on guideline 
recommendations and clinical practice.
HTA organisations should drive improvements in the 
design and rigour of randomised trials. The evolving 
landscape of cardiovascular healthcare technologies and 
related trials presents a challenge for HTA organisations 
and healthcare providers. The rapid turnover of evidence 
is externally relevant because the period from the 
trial publication to implementation of HTA guideline 
recommendations by healthcare providers may be 
prolonged, by which time new evidence may have 
emerged from subsequent trials. Implementation of a 
cardiovascular healthcare technology including be it 
a medical device, diagnostic or intervention may have 
profound implications for healthcare providers. These 
technologies may have high absolute costs and access 
may be influenced by socioeconomic and geographic 
factors.
IntroduCtIon
Innovative technologies drive advances in 
cardiovascular healthcare. Novel technol-
ogies may target a new indication, a gap in 
healthcare or simply improve the standard 
of care. Beyond medical altruism and human 
invention, technological advances are ener-
gised by commercial factors. Ultimately, 
service user access to new technologies, such 
as CT coronary angiography, is multifactorial, 
being influenced by infrastructure, funding 
streams and local expertise. This is espe-
cially the case in cardiovascular healthcare. 
Health Technology Assessment (HTA) varies 
between countries. HTA organisations may 
be nonexistent. There may or may not be a 
legislative requirement for HTA reviews to be 
considered and/or used by government in 
decision-making for healthcare. A summary 
of HTA organisation by country is shown in 
table 1.
Access to new healthcare technologies in the 
National Health Service (NHS) in England 
and Wales is guided by the National Institute 
of Health and Care Excellence (NICE). The 
Department of Health supports NICE and 
commissions guidance. NICE is highly valued 
by industry, healthcare providers and regula-
tors worldwide. NICE inevitably has a role in 
promoting the adoption of new healthcare 
technologies.1 Here, we consider ‘realistic 
medicine’ in cardiovascular healthcare, that 
is, personalised care which is patient-centred 
and minimises unwarranted variation in prac-
tice and reduces harm and waste.2 3
We draw attention to the issue of bias 
within cardiovascular trials and highlight the 
role that NICE and other HTA organisations 
might adopt to drive improvements in the 
standards of trials and quality of evidence.
nICE guIdanCE for CardIovasCular 
hEalthCarE tEChnologIEs
Groves et al1 review the role of NICE in 
promoting innovative cardiac technologies. 
The authors are leaders of the NICE Medical 
Technologies Evaluation Programme and 
Centre for Health Technology Evaluation. 
Their review presents an informative insight 
into how NICE evaluates medical technology 
for the cardiovascular system. Since 2009, 
33 Medical Technology Guidance (MTG) 
documents have been issued, including 7 
on medical technologies appraisals, 3 on 
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diagnostics, and 23 on technology innovations relating to 
the cardiovascular system.
The Diagnostic Advisory Committee of NICE reviews 
diagnostic technology if there is a potential to improve 
health outcomes, even if there is a cost increase to the 
NHS. Specifically, MTGs are published for innovative 
technologies that have patient benefits and are associ-
ated with cost savings to the NHS. Interventional Proce-
dures Guidance (IPG) summarises the safety and efficacy 
of innovative procedures. Since 2003, 73 IPGs have been 
published on the cardiovascular system, notably for Tran-
scatheter Aortic Valve Implantation (IPG 586, July 2017). 
Technology appraisals are focused on potential health 
benefits and cost-effectiveness.
Effective, timely coordination between NICE 
programmes that work in parallel is important. By way of 
example, Groves et al1 cite the Diagnostic Guidance issued 
on a new generation of CT scanners for coronary artery 
imaging and the high-sensitivity troponin assays used for 
the early rule-out of non-ST segment elevation myocar-
dial infarction. Both documents link contemporaneously 
to the NICE Clinical Guideline-95 (CG95)4 update on the 
assessment and diagnosis of chest pain. The MTG32 on 
fractional flow reserve-CT by HeartFlow was also timed to 
link with the CG95 update.5 These are examples of effec-
tive coordination between review groups within an HTA 
organisation.
WIdEr ImplICatIons of nICE for CardIovasCular 
hEalthCarE
NICE acts at the interface where innovative cardiovas-
cular technologies meet the NHS. The healthcare land-
scape is broad and complex, extending across primary 
and secondary care, academia, industry, government, 
patients and the public, and realistic medicine is increas-
ingly advocated.2 3
Key strengths of the NICE approach include involve-
ment of experts from relevant disciplines and engage-
ment with stakeholders including professional societies, 
industry and the public. However, the variable quality of 
evidence, for example, from open-label trials, advances in 
technology and turnover of trials, present key challenges 
for HTA organisations when developing guidance on 
cardiovascular healthcare technologies. Open-label trials 
are the norm opening the door to bias and impaired clin-
ical evidence. Blinded, sham (placebo)-controlled trials 
of technologies (or linked strategies) are rare but all the 
more impactful.6 7 By contrast, a randomised, double-
blinded, placebo-controlled design is the established 
norm for evaluating medicines. This disparity inevitably 
reduces the quality of evidence for cardiovascular tech-
nologies compared with medicines and becomes prob-
lematic when the quality of the evidence is discounted 
by HTA organisations and practice guideline commit-
tees. For example, the classes of guideline recommen-
dations (I–III) and levels of evidence (A–C) are directly 
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influenced by the number of trials but calibration based 
on the quality of evidence is unclear.8
The regulatory approval process for medical devices 
and drugs differs. In Europe, medicines are overseen 
by the European Medicines Agency, which requires 
evidence of clinical effectiveness and safety before regu-
latory approval. There is no single agency designated 
for licensing devices in Europe.9 In fact, multiple agen-
cies may provide (or reject) approvals for device use, 
meaning a device may be endorsed by one agency and 
not by another. Weaker forms of evidence seem to be 
sufficient for approval of medical technologies, including 
diagnostics and implantable devices. One case in point 
is the Nanostim leadless pacemaker which was licensed 
based on 90-day follow-up information in 30 patients. 
The device was granted a Conformité Européenne (CE) 
mark by the British Notified Body, British Standards Insti-
tution, whereas the German notified body turned down 
the application. In 2016, St Jude Medical halted the avail-
ability of the device because of battery issues.10 However, 
a lack of postmarketing safety information has raised 
concerns about this device and the regulatory process 
overall. Furthermore, there is no unifying registry for 
postmarketing reporting of adverse events. A test or 
device may inherit approval status related to historical 
products. One example of this is the transvaginal mesh 
which was marketed in Europe and the USA using equiv-
alence data, however, issues with the new device emerged 
in relation to unexpected side effects.11 12
QualIty of EvIdEnCE: should hta organIsatIons bE a 
drIvEr for ChangE?
Internal validity and the risk of bias
Clinical trials of medical devices, diagnostics and inter-
ventions are susceptible to bias, more so than place-
bo-controlled trials of new medicines. Open-label tech-
nology trials are the norm mainly due to logistical and/
or cost reasons, meaning the investigators, clinicians and 
patients are unblinded. Unlike in trials of cardiovascular 
medicines, active comparators for imaging interven-
tions, for example, CT coronary angiography, may not 
be adopted on grounds of cost and logistics. A cardio-
vascular intervention may have an obvious effect, for 
example, surgical scar, limiting blinding. Cardiovascular 
healthcare is a specialised field and professional bias may 
be operative. For example, a clinician who is trained and 
employed to undertake cardiovascular imaging may be 
susceptible to overt or subconscious bias if s/he is an 
investigator in a trial of an imaging-based intervention 
versus an alternative non-imaging intervention. Commer-
cial influences may also be relevant relating to reimburse-
ments (in-kind or direct) to the provider (physician, 
hospital or sponsor) for the use of a device for example, 
coronary stent.
The guidance issued by HTA organisations is a func-
tion of the available clinical evidence, the quality of the 
evidence, its cost-effectiveness and the overall approach 
of the organisation to developing the guidance (table 1). 
In decision-making, HTA committees may take account 
of evidence quality and quantity as well as sources of bias 
and whether or not interventions were blinded to the 
operator, the patient and the assessor. Bias may not be 
obvious and so difficult to identify and quantify. None-
theless, we are unclear about how bias is quantified and 
whether there is a standardised approach to qualify 
the strength of the recommendation according to the 
quality of clinical evidence. NICE periodically updates 
its methods and in doing so is guided by the developing 
thinking of research designers and HTA methodologists 
who work with NICE and stakeholders’ comments.
ExamplEs of potEntIal bIas In CardIovasCular 
tEChnology trIals
Bias impairs the quality of the evidence in several ways.13 
Types of bias in clinical trials are summarised in table 2. 
Clinical evidence that is demeaned by bias will have an 
undesirable impact on society. Consider a large, multi-
centre, randomised controlled trial. Is this synonymous 
with high-quality evidence? We think not, and this is 
especially relevant to cardiovascular technologies. There 
are multiple mechanisms by which bias impairs the 
quality of evidence from a randomised trial of a cardio-
vascular healthcare technology. Allocation concealment 
is commonly not implemented in technology trials on 
grounds of logistics and costs. In an open-label trial, the 
study procedures and standard care management become 
susceptible to the effects of overt and unmeasured bias. 
The investigators may have professional interests in the 
intervention, for example, radiologists participating as 
investigators in a trial of two clinical strategies, one with 
imaging and the other without. This scenario raises the 
potential of professional and academic bias. In a strategy 
trial, clinician enthusiasm to gain access to a new tech-
nology (the intervention) may reduce the quality of 
standard of care in the control group. Another scenario 
is where the eligibility criteria of a trial are designed to 
enrich it with ‘responders’, rendering the trial popu-
lation less representative of all-comers and reducing 
external validity.
Consider a novel diagnostic test being assessed for 
noninferiority versus the standard care test. By design, 
the likelihood of noninferiority criteria being met is 
enhanced if the trial is enriched with patients with mild 
disease (low adverse event rate) which, in turn, increases 
the true (actual) noninferiority margins compared with 
the predicted margin. Withdrawal rates, potentially of 
non-responders, may be appreciable. For these reasons, 
the per-protocol analysis of a noninferiority trial has 
key importance. If the primary outcome is linked to the 
randomised strategy (eg, coronary revascularisation in a 
trial of two invasive tests of coronary stenosis severity, and 
the decision to perform revascularisation is at the discre-
tion of an unblinded investigator), then the primary 
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Table 2 Potential sources of bias in clinical trials
Bias type Definition and examples Identifiable Quantifiable
Academic bias The investigators leading study are advocates for the intervention. Y Y
Ascertainment bias Un-blinded study design in which the outcome evaluations are susceptible to unmasked 
observer detection bias. Open-label studies, such as imaging and device trials (without a 
sham) are susceptible to ascertainment bias
Y Y/N
Comparison group bias If incorrect control/sham group is chosen, the intervention may appear to be more, or less, 
effective
Y N
Fraud bias Intentional fraud (rare) Y Y
Funding availability bias Focus of studies on questions more readily funded (commercial interest) Y/N Y/N
Hidden agenda bias Study designed to demonstrate a prerequired answer. Y/N Y/N
Intervention bias Effects of a learning curve when investigating a new technology Y/N Y/N
Measurement bias Measurement influences the respondent’s behaviour and responses, reflecting ‘response 
shift’ and relatedly a Hawthorne effect. This becomes relevant if there is an interaction 
between the intervention and the measurement tool (eg, a training effect)
Y/N Y/N
Observer bias Patients allocated to treatment arm followed more intensely/more favourably Y/N Y/N
Publication bias Positive results are more likely to get published Y Y/N
Regulation bias Overly restrictive or permissive review boards confounding the path to first-patient in Y/N Y/N
Sample choice bias Exclusion of minority groups (recruitment bias), older groups (age bias) and women (sex 
bias)
Y Y/N
Selection bias Exclusion of potentially eligible patients Y Y/N
Selective reporting bias Selective reporting of positive results Y Y
Withdrawal bias Handling missing data: Are the number of withdrawals and their reasons stated in the 
report? Are the number of withdrawals similar in each of the groups, or not? Is the 
overall number of withdrawals comparable to the number of patients that contribute to a 
difference in the primary outcome?
Y Y/
Wrong design bias Incorrect study design to answer a question (eg, a randomised study rather than post-
approval outcome research)
Y Y/N
outcome becomes highly susceptible to ascertainment 
bias.
The timing of randomisation is relevant.14 If the inter-
vention (eg, an imaging scan) is performed after rando-
misation, and if the randomised assignment was known 
to the imaging staff performing the scan, scan quality and 
compliance may be affected. In a trial without allocation 
concealment, administration of the interventions may be 
susceptible to bias. For example, in a comparative effec-
tiveness trial of an imaging intervention (eg, CT coronary 
angiography), the protocol may involve local site reads and 
local decisions; however, the trial may also include checks 
of the imaging scans by the lead site (for quality assurance 
and compliance with protocol) but without similar checks 
of the quality of the intervention in the standard care 
group (eg, treadmill exercise testing, invasive coronary 
angiography). Standard care medications may be affected, 
such as enhanced treatment in the active group and/or 
diminished treatment in the control group. Prescription 
of evidence-based medicines or procedures may be less 
than expected for the level of risk or disease burden in the 
control group. Follow-up contacts by the investigators may 
be influenced by group assignment for example, more 
frequent patient contacts (documented or not) in the 
active group compared with the control group. Therefore, 
when considering the results of a randomised controlled 
trial, are the results achieved the direct consequences of 
the intervention, an increase in standard care in the active 
group, a reduction in standard care in the control group 
or a combination of these factors? The answer may be 
difficult, if not impossible, to quantify. Bias may be imper-
ceptible and difficult to quantify, but this is no reason for 
neglect. One example is measurement and reactivity bias 
(table 2). The Measurement Reactions in Trials study has 
been commissioned by the Medical Research Council/
National Institute of Health Research Methodology 
Research Programme to develop expert guidance on how 
to avoid bias due to measurement reactivity in randomised 
trials of interventions to improve health.15
Academic and commercial conflicts of interest may 
influence the design and conduct of trials involving 
healthcare technologies. If the sponsor of the trial also 
funds the trial and owns the technology (an indus-
try-sponsored study), then academic and commercial 
interests are linked. It is not in the commercial interest 
of a company, or investigators with proprietary or profes-
sional interests, to deliver a ‘negative trial’; therefore, 
a critical appraisal of the design of the trial becomes 
important when considering the quality of the evidence, 
and related practice guideline recommendations.
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Examples of guideline-changing trials that were susceptible 
to bias
The Scottish COmputed Tomography of the HEART 
(SCOT-HEART) was an open-label clinical trial that 
took place in chest pain clinics in NHS Scotland. 
Standard care was guideline-directed patient manage-
ment mainly based on treadmill exercise testing. The 
intervention was standard care guided by an additional 
CT coronary angiogram. The control group followed 
standard care but there was no additional test (active 
or sham). The intervention was randomly allocated 1:1 
in 4146 participants with stable chest pain. The trial 
had an open-label design and the intervention was 
unmasked. The primary endpoint of the study was the 
proportion of patients diagnosed with angina pectoris 
secondary to coronary heart disease at 6 weeks. The 
clinicians who determined the primary outcome were 
familiar with the treatment group of the participants.16 
SCOT-HEART was a ‘positive’ trial in favour of the 
CT-guided strategy but by design the primary outcome 
was therefore susceptible to bias. On the other hand, 
unexpectedly, symptoms and quality of life (secondary 
outcomes) improved less with the CT-guided strategy 
as compared with standard care. Nonetheless, the 
updated NICE-95 clinical guidelines recommended CT 
coronary angiography as the first-line test for patients 
with stable chest pain. The CG95 guideline update 
issued in November 2016 did not mention the Clinical 
Evaluation of Magnetic Resonance Imaging in Coro-
nary heart disease 2 trial that had been published in 
September 2016. This trial presents evidence in favour 
of stress imaging over CT coronary angiography17 and 
highlights the importance of updates that take account 
of new evidence. A summary of the major published 
and ongoing diagnostic strategy trials in patients with 
suspected ischaemic heart disease is shown in table 3.
In phase III and phase IV trials in interventional cardi-
ology, coronary revascularisation is commonly included 
as a component of the primary outcome. This proce-
dure is triggered by a medical decision and the primary 
outcome becomes susceptible to bias when the decision 
for revascularisation is made by an unblinded clinician 
who may also be an investigator in the trial. The design 
becomes all the more problematic if the revasculari-
sation event is discounted within a time period when 
revascularisation might commonly occur, for example, 
45 days18 or 60 days.19 20 The primary outcome can 
therefore be influenced by an investigator who may 
purposefully or subconsciously schedule a revasculari-
sation procedure days before or after this cut-off.
value of a placebo or sham procedure to achieve allocation 
concealment
A placebo presents the means to mitigate bias.21 A 
matched-placebo should blind the patients, the inves-
tigators and the funders of the trial. A randomised, 
double-blind, placebo-controlled trial is the reference 
approach for assessing the effects of an intervention. 
A common alternative design is the use of active-con-
trolled trials in cardiovascular populations, since a 
placebo may present unacceptable ethical implications 
in the face of withdrawal of standard care; for example, 
heart failure with reduced ejection fraction and treat-
ment with an ACE inhibitor.22 Sham-controlled trials 
are rare in the cardiovascular space. The standards of 
clinical trials of healthcare technologies generally fall 
short of placebo-controlled trials of new medicines. We 
believe it is undesirable to have different standards for 
trials involving healthcare technologies as compared 
with those with medicines.
how does nICE quantify bias in technology trials?
In the NICE manual for reviewers,23 a number of steps 
are advocated to take account of bias. Two reviewers 
should independently assess study and conference 
abstracts and report their quality. In order to reduce 
inter-rater variability, reviewers should assess clinical 
evidence using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE)24 
and the Quality Assessment of Studies of Diagnostic 
Accuracy included in Systematic Reviews (QUADAS-
2).25 QUADAS-2 is intended to assist systematic reviews 
of diagnostic accuracy studies. The GRADE approach is 
not necessarily a guideline for rating individual studies, 
rather the totality of information across several studies 
and/or systematic reviews.
The quality of a trial can be assessed using an instru-
ment such as the Jadad scale.26 Although not without 
limitations,27 the use of such a tool presents an oppor-
tunity to objectively standardise trial evaluation. The 
Jadad scale involves blinded quality assessment of 
studies to identify observer bias, but its use may be 
limited by inter-rater variability and seems insensitive 
to the different forms of bias that may be operative 
in a trial (table 2). For these reasons, we advocate an 
improved and standardised approach to identify and 
quantify bias within a trial in order to calibrate and 
qualify the strength of related guideline recommenda-
tions (table 4). We are unclear how bias is identified 
and quantified by NICE reviewers when considering 
cardiovascular technology trials. This issue becomes 
all the more relevant given that large trials are few in 
number; therefore, the quality of evidence from an 
individual trial may have a large bearing on guideline 
recommendations.
We believe that HTA organisations and regulatory 
bodies should be drivers for improvement in the design 
of randomised trials of cardiovascular technologies. 
We call for practice guideline recommendations by 
HTA organisations to be weighted on the quality of the 
evidence, not just based on whether there exist one 
or more randomised trials (eg, levels of evidence A–C 
by international societies), but that the internal and 
external validities of the trials are quantified against 
standardised criteria leading to a quality score. This 
assessment should be standardised across guidance 
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Table 3 Focus topic: contemporary multicentre strategy trials of cardiac imaging in patients with suspected stable IHD
Title Design Result
Published trials
  PROMISE
  NCT01174550
Aim: To compare CTCA versus standard care functional assessment
Setting: Hospitals in the USA
Sample size: 10 003
Primary endpoint: Death, MI, unstable angina
Compared with noninvasive functional testing, an initial 
strategy of CTCA did not improve clinical outcomes at 
a median follow-up of 2 years (primary endpoint event 
of 3.3% in the CTCA versus 3.0% in the noninvasive 
functional testing group)
  SCOT-HEART
  NCT01149590
Aim: Comparison of usual care to CTCA
Setting: Chest pain and cardiology clinics in hospitals in Scotland
Sample size: 4146
Primary endpoint: Death from coronary heart disease or nonfatal 
myocardial infarction at 5 years
Th primary endpoint was lower in the CTA group than in 
the standard care group (2.3% [48 patients] vs 3.9% (81 
patients); HR, 0.59; 95% CI, 0.41 to 0.84; p=0.004
  CE-MARC2
  NCT01664858
Aim: To assess whether unnecessary invasive coronary angiograms 
are reduced using stress perfusion CMR at 3.0 Tesla versus MPS 
versus NICE guideline-directed care
Setting: Chest pain and cardiology clinics in hospitals in the UK
Sample size: 1202
Primary endpoint: Unnecessary invasive coronary angiography 
occurring within 12 months in each arm
The primary outcome occurred in 69 (28.8%) in the NICE 
guideline-directed group, and 36 (7.5%) and 34 (7.1%) 
in the CMR and MPS groups, respectively. There was a 
statistically significant lower adjusted OR of unnecessary 
angiography in the CMR versus NICE guideline-directed 
group (0.21, p<0.001), with no difference between the 
CMR or MPS group (1.27, p=0.32)
Trials yet to publish
  ISCHEMIA
  NCT01471522
Aim: To assess whether or not an initial invasive strategy of invasive 
angiography and optimal revascularisation if feasible, in addition to 
OMT in patients with stable CAD and at least moderate ischaemia on 
noninvasive ischaemia improves health outcomes compared with OMT 
alone
Setting: Hospitals worldwide
Sample size: 8000
Time to first occurrence of cardiovascular death or nonfatal 
myocardial infarction
  DISCHARGE
  NCT02400229
Aim: To evaluate whether CTCA-based management over invasive 
coronary angiography-guided care is superior in patients with stable 
angina and an intermediate pretest probability (10%–60%) of CAD
Setting: Hospitals in Europe
Sample size: 3546
Cardiovascular death, nonfatal myocardial infarction and 
nonfatal stroke at a maximum follow-up of 4 years.
  FORECAST
  NCT03187639
Aim: To assess whether routine FFR-CT is superior, in terms of 
resource utilisation, when compared with routine clinical pathway 
algorithms recommended by NICE
Setting: Single centre in the UK
Sample size: 1400
Resource utilisation at 9 months.
  MR-INFORM
  NCT01236807
Aim: To assess whether or not stress perfusion CMR is noninferior 
to invasive coronary angiography and FFR measurement for the 
management of patients with angina
Setting: Hospitals in the UK, Europe and Australia
Sample size: 918
Death, myocardial infarction and repeat coronary 
revascularisation at 1 year
  CorCTCA
  NCT03477890
Aim: To assess the prevalence of microvascular or vasospastic angina 
and the impact of invasive coronary artery function tests, in patients 
with nonobstructive CAD
Setting: Three hospitals in the UK
Sample size: 250
The between-group difference in the reclassification rate 
of the initial diagnosis following disclosure of invasive 
coronary artery function tests
CAD, coronary artery disease;CE-MARC2, Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2; CMR, Cardiac 
Magnetic Resonance; CTCA, CT coronary angiography; FFR, fractional flow reserve;IHD, ischaemic heart disease; MI, myocardial 
infarction;MPS, myocardial perfusion scintigraphy; NICE, National Institute of Health and Care Excellence; OMT, optimised medical therapy; 
PROMISE, progesterone in recurrent miscarriage; SCOT-HEART, Scottish COmputed Tomography of the HEART.
for medicines and technologies. After all, the service 
user relies on medical technologies and medicines, so 
why should regulatory standards systematically differ? 
Should HTA bodies adopt this approach then sponsors 
of trials of nonpharmaceutical interventions are likely 
to positively respond with improvements in trial design 
in order to secure the strongest possible practice guide-
line recommendation. Adoption of bias minimisation 
procedures (eg, sham controls) into the design of tech-
nology trials will drive improvements in the quality of 
evidence that subsequently becomes available to HTA 
reviewers.
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Table 4 Quality of evidence assessment tool. (1) Is the 
study, a randomised, double-blind, placebo- (or sham-) 
controlled clinical trial? Yes / no. (2) considering the design 
of the trial, please answer the following questions:
Question to 
respondent
Investigator 
or sponsor 
response
Reviewer 
response
Supporting 
evidence 
statement
In your opinion, is 
the study associated 
with the following 
types of bias?
5-option 
response 
(strongly 
agree–strongly 
disagree) or not 
applicable
5-option response 
(strongly agree–
strongly disagree) 
or not applicable
1 Academic
2 Ascertainment
3 Comparison group
4 Fraud and/or 
misconduct
5 Funding availability
6 Hidden agenda
7 Intervention
8 Measurement
9 Observer
10 Publication
11 Regulation
12 Sample choice
13 Selection
14 Selective reporting
15 Withdrawal
16 Wrong design
Quality of evidence score = ________% .If the response to question 
1 is ’yes’, then the initial quality of evidence score is 100%. If the 
response to question 1 is ’no’, then the score is <100%. Question 
2 has 16 sub-questions, each with an ordinal response. An ordinal, 
monotonic scaling response (Likert scale) is proposed to rate the 
respondent’s perspective on evidence quality. Where the response 
relates to a binary state the extreme response would be expected. 
The response is weighted from 1 (no bias) to 5 (evidence of bias). 
The numeric responses should be added to give a summative 
score that should then be deducted from 100 and expressed as a 
percentage. The ordinal response informs the extent of impairment in 
the medical evidence relating to the study. Since accurate and precise 
measurement of bias may be difficult or impossible, the response is 
recorded using an ordinal scale. Sample choice bias may be rated 
based on evidence of exclusion of minority groups (recruitment 
bias), older groups (age bias) and women (sex bias), or, where there 
appears to be a clinically meaningful difference in the proportion of 
the trial population represented by this subgroup compared with the 
population prevalence.
a guIdElInE to ratE thE QualIty of EvIdEnCE and 
rElatEd praCtICE guIdElInE rECommEndatIons
We propose a quality of evidence guideline for adop-
tion by stakeholders in clinical research including 
investigators, sponsors, medical journals, HTA organ-
isations, professional societies and competent author-
ities. The guideline is based on a tool to identify and 
quantify evidence impairment through bias and then 
to objectively assess the quality of evidence, quantified 
in the score, to rate the strength of a practice guideline 
recommendation (table 4). The validity, reliability 
and inter-rater agreement should be assessed and the 
content optimised through prospective testing.
The questionnaire may be completed by the chief 
investigator, sponsor or independent reviewers. 
Considering respondents completing the bias assess-
ment tool, responses from investigators may differ to 
those of independent, expert reviewers. The option of 
rating by independent assessors creates the possibility 
of a reference panel and consensus responses could 
be used to identify and quantify respondent bias. The 
validity and utility of this tool merit prospective assess-
ment. As a guide, evidence of significant impairment 
may be represented by a trial with an open-label design 
and unmasked ascertainment of the primary outcome. 
A reviewing organisation may take an executive deci-
sion to increase the weighting of a score in exceptional 
circumstances, such as in the case of scientific miscon-
duct. We believe the data should be made publicly avail-
able to inform healthcare providers and service users.
turnovEr of ClInICal EvIdEnCE
A second challenge for HTA organisations is the rapidly 
changing landscape of cardiovascular healthcare tech-
nologies and related trials. Clinical trials involving 
healthcare technologies are less stringently regulated 
than clinical trials of investigational medicinal prod-
ucts (CTIMPs). There are issues with how to blind and 
randomise devices and technology (eg, trial of implant-
able cardioverter defibrillators). This context is condu-
cive to enabling the delivery of technology trials within 
shorter timescales, and more rapid turnover to the next 
trial than could be the case for new medicines through 
CTIMPs. However, there is also a risk with devices inher-
iting approval status from historical products. Certain 
healthcare technologies and devices have obtained 
market authorisation by using data of existing products 
on the market to substantiate safety and effectiveness 
data on these newer devices.
The turnover of evidence is externally relevant since 
a recommendation by a HTA organisation to imple-
ment a new technology (or technology-based clinical 
strategy) may have profound implications for health-
care. Take the CG95 guideline update (November 
2016).2 Implementing this recommendation in a NHS 
hospital requires a Radiology Department with highly 
trained multidisciplinary staff, a multidetector CT 
scanner with cardiac software and effective clinical 
administration systems. The NHS lacks the resources to 
implement the relevant changes in a uniform and timely 
manner.28 29 In the UK, a twofold to fivefold increase in 
CT coronary angiography will be needed per year to 
implement the NICE CG95.2 In a recent survey, 22 of 
70 UK regions had no identifiable accredited CT coro-
nary angiography practitioners.29 Advanced imaging 
with CT coronary angiography, cardiovascular MRI 
and positron emission tomography involve substantial 
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infrastructure and specialist staff. New guidelines that 
recommend an increase in adoption of such technol-
ogies, such as NICE CG95, have high absolute costs 
and necessitate substantial resources to be allocated. 
Trained staff are needed and a lack of staff (cardiol-
ogists, radiologists, radiographers) may be the factor 
that limits adoption. Implementing technology guide-
lines may take several years to be effected by health-
care providers during which time new trials may have 
reported leading to changes in the clinical evidence 
(table 3). This issue is much more relevant to advanced 
technologies than medicines and becomes problematic 
if the quality of evidence is impaired by suboptimal trial 
design and bias. HTA organisations and healthcare 
providers should take account of this changing land-
scape. Regular guideline updates are important to take 
account of new trials and evidence.
ExtErnal valIdIty and aCCEss to InnovatIvE 
CardIovasCular tEChnologIEs
There may be imbalances in the representation of women 
and ethnic groups in clinical trials. Such imbalances are 
externally relevant. In line with the Equality Act 2010, the 
impact of guidance on protected groups is considered by 
NICE at the guidance scoping and development stages, 
and an Equality Impact Assessment is published for each 
piece of guidance.
The geographic variations in population demographics 
may limit the generalisability and relevance of a guide-
line recommendation by a HTA organisation, notably to 
women and ethnic groups. The availability of expensive 
healthcare technologies may be associated with socio-
economic and geographic factors, potentially promoting 
inequality in access to new standards of care in the NHS.
a global pErspECtIvE on hEalth tEChnology 
assEssmEnts
Medical technologies for cardiovascular healthcare are 
often associated with high absolute costs and their avail-
ability is influenced by economics. In October 2015, the 
WHO published a global survey of responses on national 
HTA systems.30 The survey was intended to underpin 
and inform the aims of universal health coverage. Of 194 
member states, 125 nominated national agencies and 111 
responded. They were drawn from all six WHO regions. 
Total healthcare expenditure per capita (US$, 2013) 
ranged from $17 per person in Eritrea (population 5.23 
million) to $9715 per person in Norway (population 5.21 
million). There were marked differences in HTA systems 
including governance, purpose, process transparency 
and public communication. Germany, the Republic of 
Korea, Kazakhstan and Romania were the only countries 
that had these factors in place, along with mandatory 
involvement of HTA in healthcare decision-making. In 
comparison, Iceland, Monaco, Qatar and Slovenia, which 
are all high-income countries, had incomplete HTA 
systems (across a range of categories), whereas Ecuador 
($431 total healthcare expenditure per capita; popula-
tion 16.14 million), with <1/4 healthcare expenditure 
and a population >eightfold larger, had an HTA system 
which fulfilled nearly all of the WHO criteria. The WHO 
report does not address the issues of bias and impairment 
of clinical evidence.
ConClusIons
HTA organisations and regulatory bodies should be 
drivers for improvement in the quality of medical 
evidence. To this end, these organisations should rate 
the quality of medical evidence, quantify bias and scale 
the strength of guideline recommendations accordingly. 
Improvements in the design and conduct of trials of emer-
gent cardiovascular technologies would likely follow. The 
rapidly changing landscape of cardiovascular healthcare 
technologies and related trials (table 3) presents a chal-
lenge to HTA organisations and healthcare providers. 
The turnover of evidence is externally relevant since a 
recommendation from a HTA organisation to implement 
a new technology (or related clinical strategy) may have 
profound implications for providers. Socioeconomic 
factors, notably for population subgroups, may promote 
inequalities relating to new standards of care.
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